Clinal application and nursing of high-dose recombinant human erythropoietin in treatment of anemic patients with malignancies

Objective To study the clinical effect and side effect of high-dose recombinant human erythropoietin (RHEpo)on anemic patients with malignancies.Methods Eighty-six anemic patients with malignancies were randomly divided intomatched group(rhEPO 10 000 U were administered three times weekly for up to six weeks) or high-dose group (the specific use for the first 1,3 days for erythropoietin 40000U,and then in the first 6,9,12,15,18,21,24 days given erythropoietin 20000U every day).Strengthen psychological nursing,rational use of drugs,condition observation,management of complications during the course of treatment.The patients were observed for 6 weeks,and evaluated every 2 weeks.The evaluation indexes including hemoglobin value,efficient rate,blood transfusion rate,the ratings and adverse reaction.Results Hemoglobin level of high-dose group increased significantly after treatment of 2 weeks,while that of matched group increased significantly after treatment of 4 weeks.The main hemoglobin level in high-dose group was higher than those in matched group after treatment of 4 and 6 weeks(P ＜0.05).The effect rates of 2,4,6 weeks were 40.5％ 、54.8％ 、71.4％ respectively in high-dose group,higher than 19％ 、28.6％ 、50.0％ respectively in matched group (P ＜ 0.05).There were no significant differences in side effect and transfusion rate between the two groups (P ＞ 0.05).Conclusions The effect of high-dose RHEpo is better than RHEpo with common doses on anemic patients with malignancies.There is no difference in side effect between the two groups.Reasonable care plays an important role in the curative effect of RHEpo. Key words: Recombinant human erythropoietin ;  Neoplasm ;  Anemia